 |
TSO3 retains Dr. Paul S. Malchesky as scientific advisorMay 17, 2005Québec City, May 17, 2005 – As the TSO3 Inc. (“TSO3”) scientific committee is meeting for two days in Québec City, the Company is very proud to announce that it has retained Dr. Paul S. Malchesky as a scientific advisor specialized in the development and research of innovative technologies through market introduction in the medical device and chemical industries. Dr. Malchesky is joining the committee for the first time this week.Dr. Paul S. Malchesky has carried out and directed research and development in a variety of medical device and chemical related areas including sterilization processes and sterilant formulation and separation processes for diagnostic and therapeutic applications. He has published extensively in many medical fields and holds thirty one patents. “With an impressive professional background in many aspects of chemistry, engineering, microbiology and biomaterials, Dr. Malchesky brings to our scientific committee a great deal of expertise in product and process development, clinical trials, technology evaluation as well as experience in scientific publications and patenting”, said Jocelyn Vezina, CEO of TSO3. “TSO3 is pleased to work with him and looks forward to the many contributions he can provide in improving current and future products”. As former Vice President, Research and Development, Scientific Services, and Investigational Studies at STERIS Corporation – the biggest sterilization company in North America - for almost 10 years, he led research and development teams on sterilization methods supervising many scientists and engineers. Previously at the CLEVELAND CLINIC FOUNDATION from 1969 to 1992, Dr. Malchesky headed world recognized research and development efforts with a multidisciplinary team of professionals in the field of artificial organ technologies. “I am pleased to serve in this capacity with TSO3. I have been impressed with the growth of the company since its early years and recognize their technology and equipment as addressing the demanding sterilization and processing requirements for medical devices and their clinical applications”, stated Paul S. Malchesky. About the Scientific Committee TSO3’s scientific committee was founded in 1998 and groups together international specialists working in the fields of microbiology, ozone and oxidative processes, material compatibility, engineering, chemistry, biomaterials, and regulatory affairs & quality control. This committee, among other responsibilities, must confirm to the Company’s board of directors that all the work carried out complies with scientific research and medical instrumentation standards. The advisors comment on the quality of the work and make recommendations to the board. In addition to Dr. Paul S. Malchesky who now joins the committee, other members are: Charles O. Hancock, Professor Bernard Legube, Dr. Richard Marchand, James E. Whitbourne and James W. Tatalick. To get bios for those specialists, please visit TSO3’s website at the following address: http://www.tso3.com/en/conseil.htm About Paul S. Malchesky Dr. Malchesky holds a B.S. Degree in Chemistry from St. Francis College (PA), M.S. degrees in Chemistry from Case Western Reserve University in Cleveland and in Chemical Engineering from Cleveland State University in Cleveland, and a Doctorate in Engineering from Cleveland State University. He is President of the International Center for Artificial Organs and Transplantation (ICAOT) and President of Malchesky & Associates, LLC, a firm specializing in providing consulting services to the medical device and chemical industries. He is a former Vice President of Discovery and Development for NanoScale Materials, Inc. in Manhattan, KS, a company manufacturing nanomaterials, a former Vice President of Investigational Research at STERIS Corporation, Mentor, OH, and Staff Member at the Cleveland Clinic in Artificial Organs, Cleveland, OH. He is an Associate Professor of Surgery, Baylor College of Medicine, Houston, Texas, an Adjunct Staff in Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH, and an Adjunct Professor in Chemical Engineering at Kansas State University. Dr. Malchesky is active in various professional societies and is Editor-in-Chief of Artificial Organs, and is the Managing Editor of Therapeutic Apheresis and Dialysis. About TSO3 TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in 1998. TSO3 currently has 48 employees, 19 of whom work exclusively in the Research and Development department. The Company’s mission is to develop and market innovative and comprehensive sterilization solutions. TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize heat and moisture-sensitive surgical and diagnostic devices which are expensive and in high demand from the surgical suite. The ozone sterilization process is a safe, efficacious, fast and cost-effective response to evolving sterilization needs. The 125L Ozone Sterilizer by TSO3 was cleared for commercialization by Health Canada and more recently by the U.S. Food and Drug Administration (FDA). TSO3 expects the first sales in 2005. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - |
© 2005-2008 TSO3. All Rights Reserved.
